TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11125688

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Droperidol 1.25 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg and Dexamethasone 8 mg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 160
Study: 9102248

Group type: EXPERIMENTAL
Intervention: Group C: 45 ml of NaPh taken at 6 p.m. the day before and at 6 a.m. on the morning of examination
Number of subjects: 486

Group type: COMPARATOR
Intervention: Group A: 3 liters of PEG solution taken at 2 p.m. the day before examination
Number of subjects: 486

Group type: COMPARATOR
Intervention: Group B: 45 ml of NaPh solutions taken at 7 a.m. and 7 p.m. the day before examination
Number of subjects: 486
Study: 8257144

Group type: EXPERIMENTAL
Intervention: 500 mg of ciprofloxacin (regimen A)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 750 mg of ciprofloxacin (regimen B)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 400 mg of ofloxacin (regimen C)
Number of subjects: 14
Study: 3929698

Group type: EXPERIMENTAL
Intervention: Nebulised sodium cromoglycate 20 mg (in 2 ml) administered by nebuliser four times daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nebulised sodium cromoglycate
Number of subjects: 27
Study: 30035560

Group type: EXPERIMENTAL
Intervention: 8-week somatic-focused culturally adapted cognitive-behavioral therapy (CBT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 39
Study: 28869199

Group type: EXPERIMENTAL
Intervention: Mask on (ultrasonic 3D movement analysis with mask)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mask off (ultrasonic 3D movement analysis without mask)
Number of subjects: 20
Study: 27108392

Group type: EXPERIMENTAL
Intervention: HD-tDCS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional tDCS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both montages
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HD-tDCS during fMRI
Number of subjects: 60
Study: 24683571

Group type: EXPERIMENTAL
Intervention: IIPP with SCTG (test group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: IIPP without SCTG (control group)
Number of subjects: 20
Study: 22236813

Group type: EXPERIMENTAL
Intervention: Mastectomy flap fixation using fine absorbable sutures
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional wound closure method
Number of subjects: 40
Study: 20384660

Group type: EXPERIMENTAL
Intervention: 12-month health intervention programme (study circles with diet sessions and physical activities)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control programme
Number of subjects: 41
Study: 18343247

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg/d
Number of subjects: 148

Group type: COMPARATOR
Intervention: Enalapril 20 mg/d
Number of subjects: 148
Study: 15969882

Group type: EXPERIMENTAL
Intervention: Device N (Novolizer)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Device T (Turbuhaler)
Number of subjects: 0
Study: 12242325

Group type: EXPERIMENTAL
Intervention: High-speed (HS) training at 4.73 rad.s(‐1) (knee) and 3.14 rad.s(‐1) (ankle)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-speed (LS) training at 1.05 rad.s(‐1) for both joint actions
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 100
Study: 10858343

Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g once daily for 5 days at 20 mg/kg/day)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Ofloxacin (200 mg orally twice a day for 5 days at 8 mg/kg/day)
Number of subjects: 88
Study: 9105980

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Regional Supplemented General Anesthesia (RSGEN)
Number of subjects: 73
Study: 8454478

Group type: COMPARATOR
Intervention: Radiotherapy (50 Gy in 20 fractions in 28 days)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Split course radiotherapy (25 Gy in 10 fractions in 14 days followed by a 4 week rest and a further 25 Gy in 10 fractions in 14 days) plus concurrent chemotherapy (Mitomycin C on day 1 and day 43, 5FU continuous infusions on days 1‐4 and days 43‐46)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Both treatment arms (Radiotherapy and Split course radiotherapy plus chemotherapy)
Number of subjects: 212
Study: 3697941

Group type: EXPERIMENTAL
Intervention: Semiannual screening by radiologic and sputum cytologic study
Number of subjects: 6364

Group type: COMPARATOR
Intervention: Screening at a 3-year interval
Number of subjects: 6364

Group type: COMPARATOR
Intervention: No screening
Number of subjects: 6364
Study: 31338789

Group type: EXPERIMENTAL
Intervention: Emotional video clip
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral video clip (control group)
Number of subjects: 60
Study: 28869160

Group type: EXPERIMENTAL
Intervention: 3D-printed models in educational seminars
Number of subjects: 67

Group type: COMPARATOR
Intervention: PowerPoint presentation-based educational seminar
Number of subjects: 67
Study: 27658693

Group type: EXPERIMENTAL
Intervention: Tenofovir/Lamivudine (TDF/3TC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lamivudine (3TC)
Number of subjects: 0
Study: 23551390

Group type: EXPERIMENTAL
Intervention: 60:40 deproteinized bovine bone (DPBB) and autogenous bone (AB) mixture
Number of subjects: 13

Group type: COMPARATOR
Intervention: 90:10 deproteinized bovine bone (DPBB) and autogenous bone (AB) mixture
Number of subjects: 13
Study: 22589472

Group type: EXPERIMENTAL
Intervention: Deferasirox 5 mg/kg/d
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Deferasirox 10 mg/kg/d
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 20697801

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT) with docetaxel, doxorubicin and cyclophosphamide (TAC)
Number of subjects: 2072
Study: 18184893

Group type: EXPERIMENTAL
Intervention: ePedsQL (electronic version of the Pediatric Quality of Life Inventory)
Number of subjects: 92

Group type: COMPARATOR
Intervention: PedsQL paper-and-pencil mode of administration
Number of subjects: 92
Study: 16820261

Group type: EXPERIMENTAL
Intervention: Vardenafil (5, 10 or 20mg)
Number of subjects: 383
Study: 12792554

Group type: EXPERIMENTAL
Intervention: Self-management group intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Educational booklet control
Number of subjects: 45
Study: 10648326

Group type: EXPERIMENTAL
Intervention: Sufentanil 5 microg
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Sufentanil 10 microg
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Sufentanil 20 microg
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control (40 mL 1.5% mepivacaine and saline)
Number of subjects: 92
Study: 8953335

Group type: EXPERIMENTAL
Intervention: Trial A (3-day pretest, postexercise supplementation + glucose polymers/fructose pretesting + glucose polymers/glucose during testing)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Trial B (placebo during 3-day pretest + glucose polymers/fructose pretesting + glucose polymers/glucose during testing)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Trial C (placebo at all time points)
Number of subjects: 8
Study: 29200067

Group type: EXPERIMENTAL
Intervention: 125 mg of methylprednisolone administered intravenously 30 minutes before surgery
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 27138187

Group type: EXPERIMENTAL
Intervention: Atorvastatin 60 mg (AT60)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg (AT20)
Number of subjects: 46
Study: 24118369

Group type: EXPERIMENTAL
Intervention: Reading an online news article about a genetic basis for nicotine addiction and lung cancer
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Reading an online news article indicating no genetic basis for nicotine addiction and lung cancer
Number of subjects: 333

Group type: COMPARATOR
Intervention: Reading an unrelated attention control article
Number of subjects: 333
Study: 23027229

Group type: EXPERIMENTAL
Intervention: Depleted self-control strength
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Fully available self-control strength
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Low state anxiety
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: High state anxiety
Number of subjects: 143
Study: 20601853

Group type: EXPERIMENTAL
Intervention: Online, interactive sexual risk reduction intervention
Number of subjects: 650

Group type: COMPARATOR
Intervention: Waitlist null control
Number of subjects: 650
Study: 17663731

Group type: EXPERIMENTAL
Intervention: Dalteparin 5000 U s.c. daily until 20 weeks and then 5,000 U s.c. q12 h until >37 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group receiving a mean of 38 days of postpartum dalteparin
Number of subjects: 62
Study: 15643099

Group type: EXPERIMENTAL
Intervention: 20 mg oxazepam
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 10 mg oxazepam
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 30 mg oxazepam
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 10 mg and 30 mg oxazepam
Number of subjects: 34
Study: 12200754

Group type: EXPERIMENTAL
Intervention: Glucagon infusion at rates of 0.2, 0.5, 2, 6, and 8 ng.kg(‐1).min(‐1)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Glucagon infusion at rates of 6 and 8 ng.kg(‐1).min(‐1)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Glucagon infusion (all rates)
Number of subjects: 17
Study: 10206284

Group type: EXPERIMENTAL
Intervention: Tumour S-phase fraction over 17%
Number of subjects: 217

Group type: COMPARATOR
Intervention: Tumour S-phase fraction lower than 8%
Number of subjects: 217

Group type: COMPARATOR
Intervention: Tumour S-phase fraction between 8-17%
Number of subjects: 217
Study: 7762725

Group type: EXPERIMENTAL
Intervention: Public health nursing intervention consisting of telephone contacts or home visits
Number of subjects: 1654

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 1654
Study: 2181991

Group type: EXPERIMENTAL
Intervention: Recombinant human leucocyte interferon-alpha A (2.5, 5.0 or 10.0 million units/m2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (observation for 18 months without active treatment)
Number of subjects: 30
Study: 436305

Group type: EXPERIMENTAL
Intervention: Sulpiride infusion (intravenous)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oral sulpiride treatment for 5 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 11
Study: 31793084

Group type: EXPERIMENTAL
Intervention: Ultraslow full-power shock wave lithotripsy (group A)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Slow power-ramping shock wave lithotripsy (group B)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 196
Study: 31200756

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS, 7.3% NaCl) infused at 5 ml/kg ideal body weight
Number of subjects: 96

Group type: COMPARATOR
Intervention: Normal saline (NS, 0.9% NaCl)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 96
Study: 27570246

Group type: EXPERIMENTAL
Intervention: Intradiscal Biacuplasty + Conservative Medical Management (IDB+CMM)
Number of subjects: 63

Group type: COMPARATOR
Intervention: CMM-alone
Number of subjects: 63
Study: 25840597

Group type: EXPERIMENTAL
Intervention: Subcutaneous bortezomib
Number of subjects: 598

Group type: COMPARATOR
Intervention: Intravenous bortezomib
Number of subjects: 598
Study: 23990499

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) chemotherapy administered intravenously for 6 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) chemotherapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 12
Study: 21183418

Group type: EXPERIMENTAL
Intervention: Lovastatin (20‐60 mg/day), hypolipidemic diet and physical training
Number of subjects: 83

Group type: COMPARATOR
Intervention: Hypolipidemic diet and physical training
Number of subjects: 83
Study: 19331435

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 325 mg
Number of subjects: 277
Study: 16710614

Group type: EXPERIMENTAL
Intervention: HBOC (up to 6 units) in the first 12 hours
Number of subjects: 720

Group type: COMPARATOR
Intervention: Crystalloid followed by stored RBCs
Number of subjects: 720
Study: 15260910

Group type: EXPERIMENTAL
Intervention: Pindolol (maximum dose 20 mg b.i.d.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 11417267

Group type: EXPERIMENTAL
Intervention: GHB-ethanolamide (150 mg/kg i.v. followed by 150 mg/kg/h)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Midazolam (0.025 mg/kg i.v. followed by 0.025 mg/kg/h)
Number of subjects: 29
Study: 9023465

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 or 50 mg)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study: 8420065

Group type: EXPERIMENTAL
Intervention: rh-SOD
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 2950910

Group type: EXPERIMENTAL
Intervention: Isoflurane via mask (spontaneous respiration)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane via tracheal tube (spontaneous respiration)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane via tracheal tube with controlled ventilation
Number of subjects: 60
Study: 29314208

Group type: EXPERIMENTAL
Intervention: Increased lesional volume (per 10ml)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 298
Study: 27678439

Group type: EXPERIMENTAL
Intervention: Gemcabene 300 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Gemcabene 900 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 25620399

Group type: EXPERIMENTAL
Intervention: ICE
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: PC+ICE
Number of subjects: 7
Study: 24036846

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg p.o.
Number of subjects: 11

Group type: COMPARATOR
Intervention: Calcium carbonate 4,000 mg (4 X Tums Ultra 1000®) p.o. 15 min prior to nilotinib dose.
Number of subjects: 11
Study: 20837914

Group type: COMPARATOR
Intervention: PVR alone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: PVR with surgical RV remodeling
Number of subjects: 64
Study: 18380739

Group type: EXPERIMENTAL
Intervention: Electrocautery (ECH)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidopexy (SH)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultrashears (USH)
Number of subjects: 60
Study: 16227665

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11961344

Group type: EXPERIMENTAL
Intervention: Lanreotide (100 microg/h, infused intravenously over 7 h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 20
Study: 10078400

Group type: EXPERIMENTAL
Intervention: 60 mg lidocaine 2% (L2%) with epinephrine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 7.5 mg bupivacaine 0.25% (B0.25%)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 15 mg bupivacaine 0.5% (B0.5%)
Number of subjects: 90
Study: 7675271

Group type: COMPARATOR
Intervention: HBO
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: HBO + NAC (1800 mg/day)
Number of subjects: 17
Study: 2149501

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide low dose (125 mg bid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide medium dose (250 mg bid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide low dose (125 mg bid) + Hydrocortisone (20 mg bid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide medium dose (250 mg bid) + Hydrocortisone (20 mg bid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocortisone alone (20 mg bid)
Number of subjects: 0
Study: 7020916

Group type: EXPERIMENTAL
Intervention: DTIC (dimethyl triazeno imidazole carboxamide), 4 courses in 12 months, at 4.5 mg/kg/d x 10
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: DTIC therapy in patients who developed thrombocytopenia
Number of subjects: 174
Study: 30908365

Group type: EXPERIMENTAL
Intervention: Resistance training 2 times per week (G2x, 3 sets)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Resistance training 3 times per week (G3x, 2 sets)
Number of subjects: 47
Study: 30882596

Group type: EXPERIMENTAL
Intervention: Not taking antihypertensive medications
Number of subjects: 692

Group type: COMPARATOR
Intervention: Taking antihypertensive medications
Number of subjects: 692
Study: 29941057

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil (AL) 882 mg
Number of subjects: 190
Study: 27071730

Group type: EXPERIMENTAL
Intervention: Snus
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Control (no snus)
Number of subjects: 1236
Study: 25391887

Group type: EXPERIMENTAL
Intervention: Endoscopy-assisted transoral approach (EATA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: External approaches (EA)
Number of subjects: 20
Study: 23298824

Group type: EXPERIMENTAL
Intervention: Vitamin D supplement (5000 IU/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 20734049

Group type: EXPERIMENTAL
Intervention: Triple regimen (oral aprepitant 125 mg, intravenous ondansetron 32 mg, oral dexamethasone 12 mg on day 1; aprepitant 80 mg and dexamethasone 8 mg days 2-3; dexamethasone 8 mg day 4)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dual regimen (intravenous ondansetron 32 mg and dexamethasone 20 mg on day 1; dexamethasone 8 mg bid days 2-4)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Comparison of both regimens
Number of subjects: 12
Study: 18650174

Group type: EXPERIMENTAL
Intervention: First-line erlotinib followed by second-line cisplatin/gemcitabine
Number of subjects: 900

Group type: COMPARATOR
Intervention: First-line cisplatin/gemcitabine followed by second-line erlotinib
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: First-line erlotinib
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: First-line erlotinib followed by chemotherapy
Number of subjects: 900
Study: 17142138

Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg/d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Amlodipine (2.5 mg/d)
Number of subjects: 33
Study: 12617525

Group type: EXPERIMENTAL
Intervention: EMG-LODEC software for decomposition of multichannel long-term EMG signals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wavelet-based hierarchical cluster analysis algorithm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weighted averaging method using three channels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decomposition of nonclassified segments using class-mean signals
Number of subjects: 0
Study: 11729370

Group type: EXPERIMENTAL
Intervention: Sulfonylureas (n=121)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Oral medications other than sulfonylureas (n=17)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Insulin (n=28)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Diet alone (n=79)
Number of subjects: 245
Study: 9256570

Group type: EXPERIMENTAL
Intervention: Immediate treatment group (computer‐based behavioral self‐control training)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Delayed treatment group (computer‐based behavioral self‐control training after a 10-week waiting period)
Number of subjects: 40
Study: 8287662

Group type: EXPERIMENTAL
Intervention: Brisk walking (n = 48)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (n = 24)
Number of subjects: 72
Study: 3603369

Group type: EXPERIMENTAL
Intervention: Dorsal position for irradiation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Semi-lateral position for irradiation
Number of subjects: 12
Study: 30747566

Group type: EXPERIMENTAL
Intervention: 3-stride approach
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 6-stride approach
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Global positioning satellite location (L4)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Delivery length
Number of subjects: 12
Study: 30236998

Group type: EXPERIMENTAL
Intervention: Educational support (ARM1)
Number of subjects: 11609

Group type: EXPERIMENTAL
Intervention: Gender rights awareness (ARM2)
Number of subjects: 11609

Group type: EXPERIMENTAL
Intervention: Livelihoods training (ARM3)
Number of subjects: 11609

Group type: COMPARATOR
Intervention: Control area (ARM4)
Number of subjects: 11609
Study: 26742454

Group type: EXPERIMENTAL
Intervention: Cartipatch®
Number of subjects: 55

Group type: COMPARATOR
Intervention: Mosaicplasty
Number of subjects: 55
Study: 25488849

Group type: EXPERIMENTAL
Intervention: Individualized respiratory muscle training device combined with conventional physical therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Basic exercise treatments for 30 min followed by an automated full‐body workout for 20 min
Number of subjects: 20
Study: 23107387

Group type: EXPERIMENTAL
Intervention: Community-based intervention promoting protective infant feeding practices; Duration: Not specified.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Not applicable; Control group not specified.
Number of subjects: 86
Study: 20454891

Group type: EXPERIMENTAL
Intervention: High-dose B-complex vitamin and mineral supplement (Berocca(R))
Number of subjects: 215
Study: 18590758

Group type: EXPERIMENTAL
Intervention: Population-based multi-factorial lifestyle intervention
Number of subjects: 6091

Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 6091
Study: 16368826

Group type: COMPARATOR
Intervention: Rofecoxib 50 mg/d PO
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gabapentin 1.2 g/d PO
Number of subjects: 100

Group type: COMPARATOR
Intervention: Combination of rofecoxib 50 mg/d and gabapentin 1.2 g/d PO
Number of subjects: 100
Study: 14569096

Group type: EXPERIMENTAL
Intervention: ACEI (fosinopril; 20 mg/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: ARB (irbesartan; 150 mg/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 10